Promethazine plus sumatriptan in the treatment of migraine: A randomized clinical trial

Headache

Volumn 54, Issue 1, 2014, Pages 94-108

  Asadollahi, Shadi ^a   Heidari, Kamran ^b   Vafaee, Reza ^c,d   Forouzanfar, Mohammad Mahdi ^e   Amini, Afshin ^f   Shahrami, Ali ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

clinical trial; efficacy; migraine; promethazine; sumatriptan

Indexed keywords

PLACEBO; PROMETHAZINE; SUMATRIPTAN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MIDDLE AGED; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; SOMNOLENCE; THORAX PAIN; TREATMENT RESPONSE; XEROSTOMIA; YOUNG ADULT;

CLINICAL TRIAL; EFFICACY; MIGRAINE; PROMETHAZINE; SUMATRIPTAN;

ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PROMETHAZINE; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME;

EID: 84892365835     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12259     Document Type: Article

References (59)

1. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB,. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658.
2. Goadsby PJ, Lipton RB, Ferrari MD,. Migraine-current understanding and treatment. N Engl J Med. 2002; 346: 257-270.
3. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007; 27: 193-210.
4. Lipton RB, Stewart WF,. Migraine headaches: Epidemiology and comorbidity. Clin Neurosci. 1998; 5: 2-9.
5. Ferrari MD,. The economic burden of migraine to society. Pharmacoeconomics. 1998; 13: 667-676.
6. Hopkins A,. The epidemiology of headache and migraine, and its meaning for neurological services. Schweiz Med Wochenschr. 1996; 126: 128-135.
7. Silberstein SD,. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55: 754-762.
8. Capobianco DJ, Cheshire WP, Campbell JK,. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc. 1996; 71: 1055-1066.
9. Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL,. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract. 1996; 42: 36-42.
10. Lofland JH, Johnson NE, Batenhorst AS, Nash DB,. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: A managed care perspective. Arch Intern Med. 1999; 159: 857-863.
11. Chang M, Rapoport AM,. Acute treatment of migraine headache. Tech Reg Anesth Pain Manag. 2009; 13: 9-15.
12. Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012; 13 (Suppl 2): S31-S70.
13. Goadsby PJ,. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007; 13: 39-44.
14. Tfelt-Hansen P, Vries PD, Saxena PR,. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60: 1259-1287.
15. Krymchantowski AV, Filho PF, Bigal ME,. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: A double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia. 2006; 26: 871-874.
16. Lavonas EJ, Ford MD,. Antipsychotics. In:, Marx JA, Hockberger RS, Walls RM, eds. Rosen's Emergency Medicine: Concepts and Clinical Practice, 5th edn. St. Louis, MO: C.V. Mosby; 2002: 2174-2175.
17. Peroutka SJ, Jones WT,. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Ncol alleles. Neurology. 1997; 49: 201-206.
18. Ghelardini C, Galeotti N, Uslenghi C, Grazioli I, Bartolini A,. Prochlorperazine induces central antinociception mediated by the muscarinic system. Pharmacol Res. 2004; 50: 351-358.
19. Derosier FJ, Lewis D, Hershey AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics. 2012; 129: 1411-1420.
20. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA. 2007; 297: 1443-1454.
21. Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: Guideline for good clinical practice. J Postgrad Med. 2001; 47: 45-50.
22. World Medical Association. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects (Seoul, South Korea, 2008) Available at: http://www.wma.net/en/30publications/10policies/b3/.
23. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
24. Silberstein SD, Saper JR, Freitag F,. Migraine: Diagnosis and treatment. In:, Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's Headache and Other Head Pain, 7th edn. New York, NY: Oxford University Press; 2001: 121-237.
25. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: Results from the ASSET trial. Headache. 2006; 45: 973-982.
26. Lipton RB, Stewart WF, Ryan RE Jr, Saper J, Silberstein S, Sheftell F,. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials. Arch Neurol. 1998; 55: 210-217.
27. Diener HC, Peil H, Aicher B,. The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: A post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2011; 31: 1466-1476.
28. Tfelt-Hansen P, Bousser MG, Solomon S, et al. Guidelines for controlled trials of drugs in migraine. In: International Headache Society Members' Handbook. Oslo, Norway: Scandinavian University Press; 1998-1999: 111-133.
29. Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D,. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: Results of a multicenter, randomized, placebo-controlled study. Clin Ther. 2004; 26: 214-223.
30. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: Results from the ASSET trial. Headache. 2005; 45: 973-982.
31. Tfelt-Hansen P, Bach FW, Daugaard D, Tsiropoulos I, Riddersholm B,. Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: A randomised, double-blind, placebo-controlled study. J Headache Pain. 2006; 7: 389-394.
32. Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S,. Eletriptan steering committee. Eletriptan vs Sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study. Neurology. 2002; 59: 1210-1217.
33. Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ,. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol. 2001; 58: 944-950.
34. Habib AS, Reuveni J, Taguchi A, White WD, Gan TJ,. A comparison of ondansetron with promethazine for treating postoperative nausea and vomiting in patients who received prophylaxis with ondansetron: A retrospective database analysis. Anesth Analg. 2007; 104: 548-551.
35. Lewis KS,. Pediatric headache. Semin Pediatr Neurol. 2010; 17: 224-229.
36. Skidgel RA, Kaplan A, Erdos E,. Histamine, bradykinin, and their antagonists. In:, Brunton L, Chabner B, Knollman B, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 12th edn. Columbus, OH: McGraw-Hill; 2011: 920-924.
37. Hasler G, Buysse DJ, Gamma A, et al. Excessive daytime sleepiness in young adults: A 20-year prospective community study. J Clin Psychiatry. 2005; 66: 521-529.
38. Hardman JG, Limbird LE, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 9th edn. New York, NY: McGraw-Hill; 1996.
39. Palazzo MGA, Strunin L,. Anaesthesia and emesis: II. Prevention and management. Can Anaesth Soc J. 1984; 31: 407-415.
40. Peroutka SJ, Snyder SH,. Antiemetics: Neurotransmitter receptor binding predicts therapeutic actions. Lancet. 1982; 1: 658-659.
41. Bain WA, Broadbent JL, Warin RP,. Comparison of anthisan (mepyramine maleate) and phenergan as histamine antagonists. Lancet. 1949; 2: 47-52.
42. Tarkkila P, Törn K, Tuominen M, Lindgren L,. Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Acta Anaesthesiol Scand. 1995; 39: 983-986.
43. Scherl ER, Wilson JF,. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache. 1995; 35: 256-259.
44. Buzdar AU, Esparza L, Natale R, et al. Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study. Am J Clin Oncol. 1994; 17: 417-421.
45. Lackner JR, Graybiel A,. Use of promethazine to hasten adaptation to provocative motion. J Clin Pharmacol. 1994; 34: 644-648.
46. Terndrup TE, Dire DJ, Madden CM, Davis H, Cantor RM, Gavula DP,. A prospective analysis of intramuscular meperidine, promethazine, and chlorpromazine in pediatric emergency department patients. Ann Emerg Med. 1991; 20: 31-35.
47. Malamed SF,. Sedation: A Guide to Patient Management, 5th edn. California: C. V. Mosby Co., Elsevier; 2010: 95-110.
48. Braude D, Soliz T, Crandall C, Hendey G, Andrews J, Weichenthal L,. Antiemetics in the ED: A randomized controlled trial comparing 3 common agents. Am J Emerg Med. 2006; 24: 177-182.
49. Braude D, Crandall C,. Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: A randomized, double-blind, noninferiority trial. Acad Emerg Med. 2008; 15: 209-215.
50. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache. 1998; 38: 737-747.
51. Meredith JT, Wait S, Brewer KL,. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003; 21: 173-175.
52. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S,. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache. 1998; 38: 184-190.
53. Spierings ELH,. Optimum-dose determination of the triptans. Headache. 2000; 40: 433-434.
54. Lipton RB, Stewart WF, Cady RK, et al. Sumatriptan for the range of headaches in migraine sufferers: Results of the spectrum study. Headache. 2000; 40: 783-791.
55. Faiqa Q, Donald L,. Managing headache in the pediatric emergency department. Clin Pediatr Emerg Med. 2003; 4: 159-170.
56. Mackin P,. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol. 2008; 23: 3-14.
57. Justo D, Prokhorov V, Heller K, Zeltser D,. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand. 2005; 111: 171-176.
58. Shah RR,. The significance of QT interval in drug development. Br J Clin Pharmacol. 2002; 54: 188-202.
59. Peterlin BL, Calhoun AH, Siegel S, Mathew NT,. Rational combination therapy in refractory migraine. Headache. 2008; 48: 805-819.